Advertisement
AMLX vs JAZZ
Which Stock Would AI Choose? Amylyx Pharmaceuticals (AMLX) vs. Jazz Pharmaceuticals (JAZZ) Stock Comparison
Key Takeaways
- Amylyx Pharmaceuticals (AMLX) is a clinical-stage biotech whose shares surged after positive Phase 3 data for its lead candidate, avexitide.
- Jazz Pharmaceuticals (JAZZ) is a diversified, profitable commercial drugmaker generating more than $1 billion in quarterly revenue.
- The two companies occupy opposite ends of the risk spectrum: one is a momentum-driven, pre-revenue catalyst story, the other a cash-flowing portfolio business.
- Both have drawn constructive analyst sentiment, but for different reasons — trial catalysts versus durable product growth.
- Relative performance reflects their profiles, with AMLX showing sharp volatility and JAZZ offering steadier, but still meaningful, appreciation.
Introduction
This stock comparison pairs two healthcare names with very different market positioning. AMLX, Amylyx Pharmaceuticals, is an early-stage biotechnology company riding a powerful data-driven rally. JAZZ, Jazz Pharmaceuticals, is an established, revenue-generating specialty pharmaceutical company. Comparing them helps investors contrast a high-risk, high-reward catalyst story against a mature business with proven cash flows. Growth-focused traders may gravitate toward the volatility of a clinical-stage biotech, while those seeking relative stability and recurring revenue may find the established drugmaker more compelling. Understanding how each behaves across momentum, risk, and sector exposure is central to evaluating their relative appeal in the current market environment.
AMLX Overview and Recent Performance
Amylyx Pharmaceuticals is a clinical-stage biotechnology company focused on endocrine and neurodegenerative conditions. Its near-term value proposition centers on avexitide, an investigational glucagon-like peptide-1 (GLP-1) receptor antagonist being developed for post-bariatric hypoglycemia (PBH), a condition marked by dangerously low blood sugar after weight-loss surgery.
In recent weeks, AMLX has been one of the most volatile names in biotech. The pivotal catalyst was topline data from the Phase 3 LUCIDITY trial, in which avexitide met its primary endpoint, demonstrating a 55% reduction in severe hypoglycemic events versus placebo and meeting all secondary endpoints. With no FDA (Food and Drug Administration)-approved therapies currently available for PBH, the result triggered a sharp repricing of the stock, alongside a series of analyst price-target increases.
The company also capitalized on the rally by raising roughly $500 million in a stock offering, strengthening its balance sheet ahead of a potential regulatory submission. This introduced dilution but extended its cash runway. Amylyx remains pre-revenue following the 2024 withdrawal of its former ALS (amyotrophic lateral sclerosis) therapy, meaning its valuation is heavily tied to avexitide's development timeline and commercial potential.
JAZZ Overview and Recent Performance
Jazz Pharmaceuticals is a global commercial-stage biopharmaceutical company with a diversified portfolio spanning neuroscience and oncology. Its leading products include Xywav and Xyrem for sleep disorders, Epidiolex for certain epilepsies, and an expanding oncology franchise featuring Zepzelca, Ziihera, and Modeyso.
In recent market activity, JAZZ has demonstrated a more measured trajectory than its biotech counterpart, underpinned by actual product sales. The company reported strong quarterly revenue growth, with oncology and neuroscience franchises driving results, and subsequently raised its full-year revenue outlook. Key near-term developments included the regulatory clearance of Ziihera (zanidatamab) for a first-line HER2-positive gastroesophageal cancer indication, positioning it as a meaningful growth driver.
Sentiment has been tempered by several factors, including generic competition pressures in the sleep franchise, a leadership transition in its commercial organization, and a mixed readout for Zepzelca's LAGOON trial. Despite a recent pullback from highs, JAZZ has retained substantial gains over the past year, reflecting investor recognition of its growing oncology business and recurring neuroscience cash flows.
Trending AI Robots
For traders seeking a systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of its AI-driven trading tools. Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and universe of symbols. Because not every bot suits every market condition, only the strongest and most appropriate ones are featured in the Trending AI Robots section. This selection process is designed to surface tools whose recent performance and configuration align with the current environment. Browsing this page can help investors identify automated strategies that match their own risk tolerance and timeframe preferences.
Head-to-Head Comparison
The clearest contrast between these two stocks is stage of development. JAZZ generates over a billion dollars in quarterly revenue, is profitable on an adjusted basis, and funds its operations through commercial products. AMLX, by comparison, is pre-revenue and dependent on clinical and regulatory milestones, financing its operations through capital raises.
Growth drivers differ accordingly. JAZZ's growth is tied to commercial execution — uptake of Xywav, Epidiolex, and newer oncology launches such as Ziihera and Modeyso — alongside pipeline expansion. AMLX's growth hinges on a single late-stage asset, avexitide, with additional value resting on earlier pipeline programs.
Risk profiles also diverge. AMLX carries binary event risk, concentrated exposure, and high share-price volatility. JAZZ faces generic erosion in its sleep franchise, competitive pressures, and integration and leadership-transition risks, but its diversification cushions individual setbacks.
Momentum has favored both, though in different magnitudes. AMLX has exhibited far sharper relative performance driven by a discrete catalyst, while JAZZ has posted solid but comparatively steadier appreciation, punctuated by a recent pullback.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalyst profile, and relative positioning, Tickeron's AI would likely differentiate its view by objective. For trend-following strategies emphasizing momentum and catalyst strength, the AI would more likely favor AMLX, given its strong directional move and positive trial data, while acknowledging elevated volatility. For strategies prioritizing stability, diversified revenue, and lower binary risk, the AI would more likely favor JAZZ, whose recurring cash flows and broader product base support more consistent positioning. In probabilistic terms, the AI's preference depends heavily on the specific trading style and timeframe applied, reflecting the fundamentally different risk-return profiles these two healthcare stocks represent.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and JAZZ is a Hold.
AMLX's RSI Indicator ascends from oversold territory
The RSI Indicator for AMLX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 25 of the 30 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on AMLX as a result. In 63 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for AMLX just turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 55 cases where AMLX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
AMLX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AMLX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AMLX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMLX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.429) is normal, around the industry mean (8.179). P/E Ratio (-20.851) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
JAZZ's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for JAZZ moved out of oversold territory on October 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 20 of the 25 cases the stock moved higher. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on JAZZ as a result. In 61 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on October 29, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
JAZZ moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 176 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
JAZZ broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JAZZ entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.172) is normal, around the industry mean (2.904). P/E Ratio (15.428) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
JAZZ | ||
|---|---|---|
OUTLOOK RATING 1..100 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 34 | |
SMR RATING 1..100 | 44 | |
PRICE GROWTH RATING 1..100 | 47 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMLX | JAZZ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 1 day ago 80% |
| Stochastic ODDS (%) | 2 days ago 73% | 1 day ago 69% |
| Momentum ODDS (%) | 2 days ago 80% | 1 day ago 62% |
| MACD ODDS (%) | 2 days ago 79% | 1 day ago 71% |
| TrendWeek ODDS (%) | 2 days ago 82% | 1 day ago 62% |
| TrendMonth ODDS (%) | 2 days ago 83% | 1 day ago 59% |
| Advances ODDS (%) | 6 days ago 80% | 1 day ago 59% |
| Declines ODDS (%) | 10 days ago 81% | 10 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 90% | 1 day ago 64% |
| Aroon ODDS (%) | 2 days ago 87% | 1 day ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green while JAZZ’s FA Score has 0 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- JAZZ’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 4 TA indicator(s) are bullish while JAZZ’s TA Score has 5 bullish TA indicator(s).
- AMLX’s TA Score: 4 bullish, 6 bearish.
- JAZZ’s TA Score: 5 bullish, 4 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а +4.74% price change this week, while JAZZ (@Biotechnology) price change was +14.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.04%. For the same industry, the average monthly price growth was -6.45%, and the average quarterly price growth was +4.97%.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -11.00%, and the average quarterly price growth was -16.20%.
Reported Earning Dates
AMLX is expected to report earnings on Nov 05, 2026.
JAZZ is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-1.04% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement